It was shown that patients with NSCLC (treated with RT only, N = 23) with high calreticulin expression in the tumor (N = 8), tended to have significantly better overall survival (OS) compared with RT-treated patients with NSCLC with low calreticulin expression (N = 15). The gene discussed is CALR; the disease is neoplasm.